Are new vitamin D analogues in renal bone disease superior to calcitriol?

Pediatric Nephrology

Volumn 20, Issue 3 SPEC. ISS., 2005, Pages 393-398

  Salusky, Isidro B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Active vitamin D sterols; Calcitriol; Children; Chronic kidney disease; Doxercalciferol; Paracalcitol; Secondary hyperparathyroidism

Indexed keywords

19 PARACALCITOL; 22 OXACALCITRIOL; ALFACALCIDOL; ALUMINUM; CALCITRIOL; CALCIUM; DEHYDROTACHYSTEROL; DOXERCALCIFEROL; PARATHYROID HORMONE; PARICALCITOL; PHOSPHATE; PHOSPHATE BINDING AGENT; PLACEBO; STEROL DERIVATIVE; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE;

BIOCHEMISTRY; BLOOD LEVEL; BLOOD VESSEL CALCIFICATION; BONE DISEASE; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; DIALYSIS; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE COURSE; DRUG ACTIVITY; DRUG RESEARCH; EVIDENCE BASED MEDICINE; GROWTH RETARDATION; HORMONE RESPONSE; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; KIDNEY DYSFUNCTION; NONHUMAN; OSTEODYSTROPHY; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; REVIEW; SECONDARY HYPERPARATHYROIDISM; TIME;

CALCITRIOL; CHILD; ERGOCALCIFEROLS; HUMANS; KIDNEY FAILURE, CHRONIC; PARATHYROID HORMONE; RENAL OSTEODYSTROPHY;

EID: 14644392186     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00467-004-1788-2     Document Type: Review

References (64)

1. Martinez I, Saracho R, Montenegro J, Llach F (1997) The importance of dietary calcium and phosphorus in the secondary hyperparathyroidism of patients with early renal failure. Am J Kidney Dis 29:496-502 1:CAS:528:DyaK2sXivFWlsrw%3D
2. Naveh-Many T, Silver J (1990) Regulation of parathyroid hormone gene expression by hypocalcemia, hypercalcemia and vitamin D in the rat. J Clin Invest 86:1313-1319
3. Coburn JW, Maung HM (2003) Use of active vitamin D sterols in patients with chronic kidney disease, stages 3 and 4. Kidney Int 63:S49-S53 10.1046/j.1523-1755.63.s85.12.x
4. 3 in childhood renal osteodystrophy. N Engl J Med 298:238-242
5. Chan JCM, McEnery PT, Chinchilli VM, Abitbol CL, Boineau FG, Friedman AL, Lum GM, Roy S III, Ruley EJ, Strife CF (1994) A prospective, double-blind study of growth failure in children with chronic renal insufficiency and the effectiveness of treatment with calcitriol versus dihydrotachysterol. J Pediatr 124:520-528
6. Schmitt CP, Ardissino G, Testa S, Appiani AC, Mehls O (2003) Growth in children with chronic renal failure on intermittent versus daily calcitriol. Pediatr Nephrol 18:440-444
7. Kuizon BD, Goodman WG, Jüppner H, Boechat I, Nelson P, Gales B, Salusky IB (1998) Diminished linear growth during treatment with intermittent calcitriol and dialysis in children with chronic renal failure. Kidney Int 53:205-211 10.1046/j.1523-1755.1998.00724.x
8. Waller S, Ledermann S, Trompeter R, van't Hoff W, Ridout D, Rees L (2003) Catch-up growth with normal parathyroid hormone levels in chronic renal failure. Pediatr Nephrol 18:1236-1241
9. Chesney RW, Mehls O, Anast CS, Brown E, Hammerman MR, Portale A, Fallon MD, Mahan J Jr, Alfrey AC (1986) Renal osteodystrophy in children: The role of vitamin D, phosphorus, and parathyroid hormone. Am J Kidney Dis 7:275-284
10. Nussbaum SR, Zahradnik RJ, Lavigne JR, Brennan GL, Nozawa-Ung C, Kim LY, Keutmann T, Wang CA, Potts JT Jr, Segre GV (1987) Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. Clin Chem 33:1364-1367 1:CAS:528:DyaL2sXkvFSitbc%3D
11. Sherrard DJ, Hercz G, Pei Y, Maloney N, Greenwood C, Manuel A, Saiphoo C, Fenton SS, Segre GV (1993) The spectrum of bone disease in end-stage renal failure - an evolving disorder. Kidney Int 43:436-442
12. Cohen-Solal ME, Sebert JL, Boudailliez B, Marie A, Moriniere Ph, Gueris J, Bouillon R, Fournier A (1991) Comparison of intact, midregion, and carboxy-terminal assays of parathyroid hormone for the diagnosis of bone disease in hemodialyzed patients. J Clin Endocrinol Metab 73:516-524
13. Quarles LD, Lobaugh B, Murphy G (1992) Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia. J Clin Endocrinol Metab 75:145-150 10.1210/ jc.75.1.145
14. Mathias RS, Salusky IB, Harmon WH, Paredes A, Emans J, Segre GV, Goodman WG (1993) Renal bone disease in pediatric patients and young adults treated by hemodialysis in a children's hospital. J Am Soc Nephrol 12:1938-1946
15. Salusky IB, Ramirez JA, Oppenheim WL, Gales B, Segre GV, Goodman WG (1994) Biochemical markers of renal osteodystrophy in pediatric patients undergoing CAPD/CCPD. Kidney Int 45:253-258 1:STN:280:ByuC2s3psVU%3D
16. Slatopolsky E, Finch J, Clay P, Martin D, Sicard G, Singer G, Gao P, Cantor TL, Dusso A (2000) A novel mechanism for skeletal resistance in uremia. Kidney Int 58:753-761 10.1046/j.1523-1755.2000.00222.x
17. Monier-Faugere MC, Geng Z, Mawad H, Friedler RM, Gao P, Cantor TL, Malluche HH (2001) Improved assessment of bone turnover by the PTH-(1-84)/large C-PTH fragments ratio in ESRD patients. Kidney Int 60:1460-1468 10.1046/j.1523-1755.2001.00949.x
18. Coen G, Bonucci E, Ballanti P, Balducci A, Calabria S, Nicolai GA, Fischer MS, Lifrieri F, Manni M, Morosetti M, Moscaritolo E, Sardella D (2002) PTH 1-84 and PTH "7-84" in the noninvasive diagnosis of renal bone disease. Am J Kidney Dis 40:348-354 10.1053/ajkd.2002.34519
19. Salusky IB, Goodman WG, Kuizon BD, Lavigne JR, Zahranik RJ, Gales B, Wang HJ, Elashoff RM, Juppner H (2003) Similar predictive value of bone turnover using first- and second-generation immunometric PTH assays in pediatric patients treated with peritoneal dialysis. Kidney Int 63:1801-1808 1:CAS:528:DC%2BD3sXjslygsb8%3D
20. Norman ME, Mazur AT, Borden S, Gruskin A, Anast C, Baron R, Rasmussen H (1980) Early diagnosis of juvenile renal osteodystrophy. J Pediatr 97:226-232
21. Hodson EM, Evans RA, Dunstan CR, Hills EE, Shaw PF (1982) Quantitative bone histology in children with chronic renal failure. Kidney Int 21:833-839
22. Hsu AC, Kooh SW, Fraser D, Cumming WA, Fornasier VL (1982) Renal osteodystrophy in children with chronic renal failure: An unexpectedly common and incapacitating complication. Pediatrics 70:742-750
23. Smith PS, McClure J (1982) Localisation of aluminium by histochemical and electron probe x-ray microanalytical techniques in bone tissue of cases of renal osteodystrophy. J Clin Pathol 35:1283-1293
24. 3]. Histologic bone studies. Acta Pediatr Scand 73:315-324
25. Mehls O, Krempien B, Ritz E, Scharer K, Schuler HW (1973) Renal osteodystrophy in children on maintenance hemodialysis. Proc EDTA 10:197-201
26. Witmer G, Margolis A, Fontaine O, Fritsch J, Lenoir G, Broyer M, Balsan S (1976) Effects of 25-hydroxycholecalciferol on bone lesions of children with terminal renal failure. Kidney Int 10:395-408
27. Salusky IB, Coburn JW, Brill J, Foley J, Slatopolsky E, Fine RN, Goodman WG (1988) Bone disease in pediatric patients undergoing dialysis with CAPD or CCPD. Kidney Int 33:975-982
28. Hamdy NA, Kanis JA, Beneton MNC, Brown CB, Juttmann JR, Jordans JGM, Josse S, Meyrier A, Lins RL, Fairey IT (1995) Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. Br Med J 310:358-363 1:STN:280:ByqC2s%2FltFU%3D
29. Nordal KP, Dahl E (1988) Low dose calcitriol versus placebo in patients with predialysis chronic renal failure. J Clin Endocrinol Metab 67:929-936
30. 3: Humoral and histomorphometric results. Miner Electrolyte Metab 12:375-382
31. Bianchi ML, Colantonio G, Campanini F, Rossi R, Valenti G, Ortolani S, Buccianti G (1994) Calcitriol and calcium carbonate therapy in early chronic renal failure. Nephrol Dial Transplant 9:1595-1599
32. Goodman WG, Salusky IB (1991) Evolution of secondary hyperparathyroidism during daily oral calcitriol therapy in pediatric renal osteodystrophy. Contrib Nephrol 90:189-195
33. Salusky IB, Foley J, Nelson P, Goodman WG (1991) Aluminum accumulation during treatment with aluminum hydroxide and dialysis in children and young adults with chronic renal disease. N Engl J Med 324:527-531
34. Slatopolsky E, Weerts C, Thielan J, Horst RL, Harter H, Martin KJ (1984) Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxycholecalciferol in uremic patients. J Clin Invest 74:2136-2143 6549016
35. 3 pulse therapy. N Engl J Med 315:421-422
36. Quarles LD, Yohay DA, Carroll BA, Spritzer CE, Minda SA, Bartholomay D, Lobaugh BA (1994) Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD. Kidney Int 45:1710-1721
37. Levine BS, Song M (1996) Pharmacokinetics and efficacy of pulse oral versus intravenous calcitriol in hemodialysis patients. J Am Soc Nephrol 7:488-496
38. Salusky IB, Kuizon BD, Belin T, Ramirez JA, Gales B, Segre GV, Goodman WG (1998) Intermittent calcitriol therapy in secondary hyperparathyroidism: A comparison between oral and intraperitoneal administration. Kidney Int 54:907-914 10.1046/j.1523-1755.1998.00045.x
39. Greenbaum LA, Genda R, Qiu P, Restaino I, Wojtak A, Paredes A, Benador N, Melnick JZ, Williams LA, Salusky IB (2004) Intravenous calcitriol for treatment of hyperparathyroidism in children on hemodialysis. Pediatr Nephrol (in press)
40. Salusky IB, Goodman WG, Norris KC, Horst R, Fine RN, Coburn JW (1988) Bioavailability of calcitriol after oral, intravenous and intraperitoneal doses in dialysis patients. In: Norman AW, Shaefer K, v. Herrath D, Grigoleit H-G (eds) Vitamin D: Chemical, biochemical and clinical endocrinology of calcium metabolism. Walter de Gruyter, Berlin, pp 83-84
41. Andress DL, Norris KC, Coburn JW, Slatopolsky EA, Sherrard DJ (1989) Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med 321:274-279
42. Goodman WG, Ramirez JA, Belin TR, Chon Y, Gales B, Segre GV, Salusky IB (1994) Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int 46:1160-1166
43. Salusky IB, Goodman WG (2001) Adynamic renal osteodystrophy: Is there a problem? J Am Soc Nephrol 12:1978-1985
44. Kopple JD, Coburn JW (1973) Metabolic studies of low protein diets in uremia: II. Calcium, phosphorus and magnesium. Medicine 52:597-607
45. Milliner DS, Zinsmeister AR, Lieberman E, Landing B (1990) Soft tissue calcification in pediatric patients with end-stage renal disease. Kidney Int 38:931-936
46. Foley RN, Parfrey PS, Sarnak MJ (1998) Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32:S112-S119
47. Oh J, Wunsch R, Turzer M, Bahner M, Raggi P, Querfeld U, Mehls O, Schaefer F (2002) Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Circulation 106:100-105 10.1161/01.CIR.0000020222.63035.C0
48. Brown AJ, Ritter CR, Finch JL, Morrissey J, Martin KJ, Murayama E, Nishii Y, Slatopolsky E (1989) The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion. J Clin Invest 84:728-732
49. Brown AJ, Finch J, Grieff M, Ritter C, Kubodera N, Nishii Y, Slatopolsky E (1993) The mechanism for the disparate actions of calcitriol and 22-oxacalcitriol in the intestine. Endocrinology 133:1158-1164 10.1210/ en.133.3.1158
50. 2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content. Am J Kidney Dis 30:105-112
51. 3 and 22-oxacalcitriol prevent the decrease in vitamin D receptor content in the parathyroid glands of uremic rats. Kidney Int 50:34-39
52. Hirata M, Katsumata K, Masaki T, Koike N, Endo K, Tsunemi K, Ohkawa H, Kurokawa K, Fukagawa M (1999) 22-Oxacalcitriol ameliorates high-turnover bone and marked osteitis fibrosa in rats with slowly progressive nephritis. Kidney Int 56:2040-2047 10.1046/j.1523-1755.1999.00772.x
53. Monier-Faugere MC, Geng Z, Friedler RM, Qi Q, Kubodera N, Slatopolsky E, Malluche HH (1999) 22-Oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure. Kidney Int 55:821-832 10.1046/j.1523-1755.1999.055003821.x
54. Kurokawa K, Akizawa T, Suzuki M, Akiba T, Ogata E, Slatopolsky E (1996) Effect of 22-oxacalcitriol on hyperparathyroidism of dialysis patients: results of preliminary study. Nephrol Dial Transplant 11:121-124
55. Tsukamoto Y, Hanaoka M, Matsuo T, Saruta T, Nomura M, Takahashi Y (2000) Effect of 22-oxacalcitriol on bone histology of hemodialyzed patients with severe secondary hyperparathyroidism. Am J Kidney Dis 35:458-464
56. 2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia. Am J Kidney Dis 26:852-860
57. Sprague SM, Lerma E, McCormmick D, Abraham M, Batlle D (2001) Suppression of parathyroid hormone secretion in hemodialysis patients: comparison of paricalcitol with calcitriol. Am J Kidney Dis 38:S51-S56
58. Teng M, Wolf M, Lowrie EG, Ofsthun N, Lazarus JM, Thadhani RI (2003) Survival of patients undergoing hemodialysis with paracalcitol or calcitriol therapy. N Engl J Med 349:446-456 10.1056/NEJMoa022536
59. 3 in the rat. Proc Soc Exp Biol Med 178:432-436
60. 2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism. Kidney Int 51:317-323
61. Frazao J, Chesney RW, Coburn JW (1998) Intermittent oral 1alpha-hydroxyvitamin D2 is effective and safe for the suppression of secondary hyperparathyroidism in haemodialysis patients. 1alphaD2 Study Group. Nephrol Dial Transplant 13 Suppl 3:68-72 10.1093/ndt/13.suppl_3.68
62. Coburn JW, Maung HM, Elangovan L, Germain MJ, Lindberg JS, Sprague SM, Williams ME, Bishop CW (2004) Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4. Am J Kidney Dis 43:877-890 10.1053/j.ajkd.2004.01.012
63. Chertow GM, Burke SK, Raggi P (2002) Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62:245-252 10.1046/j.1523-1755.2002.00434.x
64. Joy MS, Finn WF, LAM-302 Study Group (2003) Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: A new phosphate binder for the treatment of hyperphosphatemia. Am J Kidney Dis 42:96-107 10.1016/S0272-6386(03)00554-7